Clinical trials: Impaired Glucose Metabolism
Diabetes Mellitus, Type 2
A Pharmacokinetic Study of MK-3102 in Participants With Impaired Hepatic Function (MK-3102-031)
This study will investigate and compare the pharmacokinetics of a single 25-mg dose of MK-3102 in participants with moderate hepatic impairment and matched healthy participants.
- Trial name
- NCT01767688
- Testing
- MK-3102
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Heart Failure, Type 2 Diabetes Mellitus
Effect of Sotagliflozin on Cardiovascular and Renal Events in Participants With Type 2 Diabetes and Moderate Renal Impairment Who Are at Cardiovascular Risk
The primary objective of the study was to compare the effect of sotagliflozin to placebo on total occurrences of cardiovascular (CV) death, hospitalization for heart failure [HHF], and urgent visit for heart failure [HF] in…
- Conditions
- Heart Failure, Type 2 Diabetes Mellitus, Chronic Kidney Diseases
- Trial name
- SCORED (NCT03315143)
- Testing
- Sotagliflozin
- Where
- 754 sites in United States, Argentina and 43 more
- Volunteers
- 10,584 people
- Sponsor
- Lexicon Pharmaceuticals
Diabetic Retinopathy, Macular Oedema
Ranibizumab Treatment of Diabetic Macular Oedema With Bimonthly Monitoring After a Phase of Initial Treatment
This study evaluates a new investigational treatment regimen of three consecutive monthly doses of ranibizumab followed by an as-needed treatment regimen, with monthly follow-up for the first three months then two-monthly…
- Trial name
- RELIGHT (NCT01257815)
- Testing
- Ranibizumab
- Where
- 15 sites in United Kingdom
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Impaired Glucose Tolerance
GLU-xx Formulations in Individuals With Impaired Glucose Tolerance
The purpose of this study is to determine a safe,tolerable and efficacious dose of GLU-xx.
- Trial name
- NCT01468376
- Testing
- GLU-01, GLU-02, GLU-03
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Afexa Life Sciences Inc
Glucose Lowering
To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients
To assess the pharmacokinetics of AZD1656, and its metabolite, in type 2 diabetes mellitus patients with varying degrees of renal impairment and to compare the results with those in patients with normal renal function.
- Trial name
- NCT01069926
- Testing
- AZD1656
- Where
- 4 sites in United States
- Volunteers
- 21 people
- Sponsor
- AstraZeneca
Impaired Glucose Tolerance
Dose-dependent Effect of Grape Seed Extract on Glucose Control in People With Impaired Glucose Tolerance
The objective is to identify the lowest effective dose of Grape Seed Extract (GSE) on glucose control in people with impaired glucose tolerance (IGT).
- Trial name
- GSE3 (NCT02254317)
- Testing
- 300 mg GSE, 600 mg GSE, 900 mg GSE
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
Diabetes Mellitus, Type 2
Renal Impairment Study of Empagliflozin (BI10773) in Japanese Patients With Type 2 Diabetes
The objective of this study is to assess the effect of the different degrees of renal impairment on the pharmacokinetics, pharmacodynamics and safety of BI10773 following oral administration of high dose BI10773 as a single dose…
- Trial name
- NCT01581658
- Testing
- BI10773
- Where
- Japan
- Volunteers
- 32 people
- Sponsor
- Boehringer Ingelheim
Mild Cognitive Impairment, Metabolic Syndrome
Dietary Ketosis: Fatty Acids Activate AMPK Energy Circuits Modulating Global Methylation
The study explores whether selective memory complaints (SMC), mild cognitive impairment (MCI) and the comorbidity of Metabolic Syndrome symptomatic of peripheral and cerebral hypo-metabolism with corresponding epigenetic shifts…
- Trial name
- NCT03319173
- Testing
- Dietary intervention
- Where
- United States
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Bristlecone Health, Inc.
Diabetes Mellitus
Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment
This is a bi-centric, prospective, open study comparing the effects of linagliptin on active GLP-1 concentrations in subjects with renal impairment compared to subjects with normal renal function.
- Trial name
- NCT01903070
- Testing
- Linagliptin
- Where
- Germany
- Volunteers
- 99 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Type II Diabetes Mellitus
Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency
This is an open-label, single-dose, Phase 1 clinical study designed to evaluate the effect of renal impairment on the pharmacokinetics (PK) of GL0034, a long-acting GLP-1 receptor agonist.
- Trial name
- NCT07385547
- Testing
- GL0034
- Where
- 3 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries Limited
Diabetes, Diabetes Mellitus, Type 2
Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney Function
This trial is conducted in Oceania. The aim of this trial is to assess whether dose adjustment is required for patients with renal impairment by investigating the pharmacokinetics of liraglutide in subjects with various degrees…
- Trial name
- NCT01508806
- Testing
- liraglutide
- Where
- Australia
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH)
A Single-Dose Pharmacokinetic Study of HRS-4729 Injection in Healthy Participants and Patients With Renal Impairment
This study aims to evaluate the pharmacokinetic effects of a single dose of HRS-4729 injection in participants with mild, moderate, and severe renal impairment, with 8 participants enrolled in each renal impairment group and 8…
- Conditions
- Overweight/Obesity, Metabolic Dysfunction-associated Steatotic Liver Disease/Steatohepatitis (MASLD/MASH), Type 2 Diabetes Mellitus
- Trial name
- NCT07807059
- Testing
- HRS-4729
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Diabetes
Pharmacokinetic and Safety Study of GZR4 Injection in Subjects With Hepatic Impairment
This is a multicenter, single-dose, open-label, parallel Phase 1 clinical study to evaluate the PK profile, safety, and tolerability of GZR4 Injection in subjects with mild, moderate, and severe hepatic impairment.
- Trial name
- NCT07193147
- Testing
- GZR4
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
HbA1c Level Associated With Lipid Compositions
to Evaluate the Safety and Efficacy of Pitavastatin in Patients With IFG and Hyperlipidemia
Primary Objective : To evaluate that there is no different effect on HbA1c between routine lipid lowering therapy(Livalo 2mg) and intensive lipid lowering therapy(Livalo 4mg) in the hyperlipidemic patients with impaired fasting…
- Trial name
- SIPHON (NCT02056847)
- Testing
- Pitavastatin calcium 4mg, Pitavastatin calcium 2mg
- Where
- South Korea
- Volunteers
- 313 people
- Sponsor
- JW Pharmaceutical
Diabetes, Diabetes Mellitus, Type 2
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Hepatic Impairment
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of oral semaglutide (NNC0113-0217) in subjects with mild…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02016911
- Testing
- semaglutide
- Where
- 6 sites in Czechia, Poland and 1 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Pharmacokinetics, Safety and Tolerability of Oral Semaglutide in Subjects With Various Degrees of Impaired Renal Function
This trial is conducted in Europe. The aim of the trial is to investigate the pharmacokinetics (the exposure of the trial drug in the body), safety and tolerability of oral semaglutide in subjects with various degrees of impaired…
- Conditions
- Diabetes, Diabetes Mellitus, Type 2, Healthy
- Trial name
- NCT02014259
- Testing
- semaglutide
- Where
- 4 sites in Czechia, Hungary
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Type 2 Diabetes Mellitus
A Study to Assess the Pharmacokinetics, Pharmacodynamics of ASP1941 in Diabetes Mellitus Patients With Renal Impairment
The primary objective of this study is to compare the pharmacokinetics of ASP1941 in type 2 diabetes mellitus patients with normal renal function and those with mild or moderate renal impairment.
- Trial name
- NCT01097681
- Testing
- ASP1941
- Where
- 2 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Astellas Pharma Inc
Diabetic Macular Edema, Visual Impairment
A 12-month, Randomized, Efficacy and Safety Study of 0.5 mg Ranibizumab vs Laser in Chinese Diabetic Macular Edema (DME) Patients
Study of efficacy and safety of 0.5 mg ranibizumab in Chinese patients with diabetic macular edema (DME)
- Trial name
- REFINE (NCT02259088)
- Testing
- Ranibizumab (RFB002), Laser
- Where
- 28 sites in China
- Volunteers
- 384 people
- Sponsor
- Novartis Pharmaceuticals
Pre-diabetes
A Study to Evaluate the Effects of Vildagliptin on the Insulin Response to Glucose in Subjects With Pre-diabetes
This is an exploratory study to assess whether vildagliptin, an unapproved drug, can increase insulin secretion in subjects with pre-diabetes who have a defect in the insulin response and elevated levels of fasting glucose.
- Trial name
- NCT00312130
- Testing
- Vildagliptin
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Novartis